Treace Medical Concepts (NASDAQ:TMCI) Issues Earnings Results

Treace Medical Concepts (NASDAQ:TMCI) issued its earnings results on Friday. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.03, FiscalAI reports. Treace Medical Concepts had a negative net margin of 27.74% and a negative return on equity of 59.91%. The company had revenue of $47.20 million during the quarter, compared to analysts’ expectations of $45.96 million.

Here are the key takeaways from Treace Medical Concepts’ conference call:

• Q1 revenue was $47.2 million, down ~10% year‑over‑year, with a net loss of $18.0 million and an adjusted EBITDA loss of $5.5 million, driven by lower bunion kit volumes and a shift toward lower‑priced products.
• Management reaffirmed full‑year 2026 guidance of $202–$212M in revenue (‑5% to 0% vs. 2025) and expects adjusted EBITDA loss of $4–$6M, while targeting a roughly 50% reduction in cash usage versus 2025.
• Commercial traction is building for the 2025 product launches — about 35% of Lapiplasty surgeons have adopted at least one of the three new bunion systems (up from 25% in Q4), and ~30% of new surgeons who started with those systems have also used Lapiplasty, indicating early pull‑through.
• The product roadmap is expanding — full commercialization of SuperBite and SpeedXM is expected in Q3 and Lapiplasty Lightning later this year, collectively increasing the addressable market by roughly $300M and opening access to higher‑ASP midfoot and hindfoot procedures.
• Management noted persistent macro pressure on elective procedures and an ASP/mix headwind from rapid adoption of lower‑priced MIS products that pressured top‑line results, though they expect these dynamics to abate in the back half and for growth to return in Q4.

Treace Medical Concepts Stock Up 4.7%

Shares of NASDAQ TMCI opened at $2.01 on Friday. Treace Medical Concepts has a 1 year low of $1.17 and a 1 year high of $7.78. The firm’s 50 day moving average price is $1.62 and its 200 day moving average price is $2.65. The firm has a market cap of $130.22 million, a P/E ratio of -2.14 and a beta of 1.10. The company has a debt-to-equity ratio of 0.64, a quick ratio of 3.13 and a current ratio of 4.31.

Analysts Set New Price Targets

A number of brokerages have issued reports on TMCI. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Treace Medical Concepts in a report on Monday, April 20th. Wall Street Zen raised shares of Treace Medical Concepts from a “strong sell” rating to a “sell” rating in a report on Monday, April 27th. Finally, Lake Street Capital dropped their target price on shares of Treace Medical Concepts from $7.50 to $7.00 and set a “buy” rating for the company in a report on Monday, March 2nd. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus price target of $4.77.

Institutional Trading of Treace Medical Concepts

Hedge funds have recently bought and sold shares of the company. Quadrature Capital Ltd acquired a new position in shares of Treace Medical Concepts in the 4th quarter valued at $149,000. Engineers Gate Manager LP acquired a new position in shares of Treace Medical Concepts in the 4th quarter valued at $109,000. Wells Fargo & Company MN boosted its holdings in shares of Treace Medical Concepts by 66.7% in the 4th quarter. Wells Fargo & Company MN now owns 52,163 shares of the company’s stock valued at $128,000 after purchasing an additional 20,870 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in shares of Treace Medical Concepts in the 3rd quarter valued at $87,000. Finally, Captrust Financial Advisors acquired a new position in shares of Treace Medical Concepts in the 2nd quarter valued at $62,000. Institutional investors and hedge funds own 84.08% of the company’s stock.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.